IP Library › Granted Patent US 9,120,811
Granted Patent B2
US 9,120,811 · App. 14/274,618 · Granted Sep 1, 2015

6-(1

Inventors: Scott A. Mitchell (East Haven, CT); Kevin S. Currie (North Branford, CT)
Assignee: Gilead Connecticut, Inc.
C07D498/04A61K31/495C07D471/04C07D487/04C07D491/107C07D519/00C12Q1/485G01N33/573
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,120,811
App. No.
14/274,618
Granted
Sep 1, 2015
Kind
B2
Abstract

Provided are imidazopyrazine compounds, including 6-(1H-indazol-6-yl)-N-(4 -moirpholinophenyl)imidazo-[1,2-a]pyrazine-8-amine: and methods for using the imidazopyrazine compounds for treating diseases and disorders responsive to the inhibition of Syk activity, including leukemia and lymphoma.

Claims (11)

1. A method for treating leukemia or lymphoma in a human in need thereof, comprising administering to the human an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the effective amount of the compound or a pharmaceutically acceptable salt thereof is administered to the human intravenously, intramuscularly, parenterally, or orally.

3. The method according to claim 1 , wherein the method is a method for treating leukemia, and the leukemia is B-cell leukemia.

4. The method according to claim 1 , wherein the method is a method for treating leukemia, and the leukemia is chronic lymphocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or hairy cell leukemia.

5. The method according to claim 1 , wherein the method is a method for treating leukemia, and the leukemia is chronic lymphocytic leukemia.

6. The method according to claim 1 , wherein the method is a method for treating leukemia, and the leukemia is acute lymphocytic leukemia.

7. The method according to claim 1 , wherein the method is a method for treating leukemia.

8. The method according to claim 1 , wherein the method is a method for treating lymphoma.

9. The method according to claim 1 , wherein the method is a method for treating lymphoma, and the lymphoma is B-cell lymphoma.

10. The method according to claim 1 , wherein the method is a method for treating lymphoma, and the lymphoma is non-Hodgkin's lymphoma.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2020
From: GILEAD CONNECTICUT, INC.
To: KRONOS BIO, INC.
Reel/Frame 053927/0969 →
MERGER AND CHANGE OF NAME Recorded Sep 17, 2020
From: COUGAR MERGER SUB, INC.; CGI PHARMACEUTICALS, INC.; CGI PHARMACEUTICALS, INC.
To: GILEAD CONNECTICUT, INC.
Reel/Frame 053799/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2014
From: MITCHELL, SCOTT A.; CURRIE, KEVIN S.; BLOMGREN, PETER A.; KROPF, JEFFREY E.; LEE, SEUNG H.; XU, JIANJUN; STAFFORD, DOUGLAS G.; HARDING, JAMES P.; BARBOSA, ANTONIO J, JR.; ZHAO, ZHONGDONG
To: CGI PHARMACEUTICALS, INC.
Reel/Frame 033703/0939 →
MERGER Recorded Sep 9, 2014
From: CGI PHARMACEUTICALS, INC.
To: GILEAD CONNECTICUT, INC.
Reel/Frame 033704/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2014
From: ARMISTEAD, DAVID M.; MITRA, SOUMYA
To: GILEAD CONNECTICUT, INC.
Reel/Frame 033704/0314 →
Continuity (6)
Continuation 13868971 · Apr 23, 2013
Division 12632140 · Dec 7, 2009
Provisional Application 61120587 · Dec 8, 2008
Provisional Application 61140514 · Dec 23, 2008
Provisional Application 61240979 · Sep 9, 2009
Related Publication 20140336169A1 · Nov 13, 2014